ADAMTS13 and von willebrand factor in thrombotic thrombocytopenic purpura

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 211-225

  Zheng, X Long ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

arterial thrombosis; autoantibodies; autoimmune disorder; metalloprotease; mutations; rare hematological disease

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY; RECOMBINANT PROTEIN;

ARTICLE; BIOSYNTHESIS; BRAIN MALARIA; CEREBROVASCULAR ACCIDENT; GENE; GENE MUTATION; GENE THERAPY; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION; NEOPLASM; PLASMA TRANSFUSION; PLASMAPHERESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE GENE; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PROCEDURES; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ADAM PROTEINS; AUTOANTIBODIES; GENETIC THERAPY; HUMANS; MUTATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECOMBINANT PROTEINS; VON WILLEBRAND FACTOR;

EID: 84921380588     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-061813-013241     Document Type: Article

References (100)

1. Moschcowitz E. 1924. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc. N.Y. Pathol. Soc. 24:21-24
2. Schulman I, Pierce M, Lukens A, et al. 1960. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 16:943-57
3. Upshaw Jr. JD. 1978. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N. Engl. J. Med. 298:1350-25
4. Rennard S, Abe S. 1979. Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome). N. Engl. J. Med. 300:368
5. Kinoshita S, Yoshioka A, Park YD, et al. 2001. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int. J. Hematol. 74:101-8
6. Amorosi E, Ultmann J. 1966. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 45:139-59
7. BellWR, BraineHG, Ness PM, et al. 1991. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N. Engl. J. Med. 325:398-403
8. Tsai HM, Lian EC. 1998. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 339:1585-94
9. Rock GA, Shumak KH, Buskard NA, et al. 1991. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 325:393-97
10. Moake JL, Rudy CK, Troll JH, et al. 1982. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 307:1432-35
11. Furlan M, Robles R, Solenthaler M, et al. 1997. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89:3097-103
12. Furlan M, Robles R, Solenthaler M, et al. 1998. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91:2839-46
13. Furlan M, Robles R, Lammle B. 1996. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223-34
14. Tsai HM. 1996. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235-44
15. Fujikawa K, Suzuki H, McMullen B, et al. 2001. Purification of human vonWillebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662-66
16. Gerritsen HE, Robles R, Lammle B, et al. 2001. Partial amino acid sequence of purified vonWillebrand factor-cleaving protease. Blood 98:1654-61
17. Zheng X, Chung D, Takayama TK, et al. 2001. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 276:41059-63
18. Levy GG, Nichols WC, Lian EC, et al. 2001. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488-94
19. Plaimauer B, ZimmermannK, VolkelD, et al. 2002. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100:3626-32
20. Zheng X, Nishio K, Majerus EM, et al. 2003. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J. Biol. Chem. 278:30136-41
21. Dong JF, Moake JL, Nolasco L, et al. 2002. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:4033-39
22. Rieger M, Ferrari S, Kremer Hovinga JA, et al. 2006. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb. Haemost. 95:212-20
23. Uemura M, Tatsumi K, Matsumoto M, et al. 2005. Localization of ADAMTS13 to the stellate cells of human liver. Blood 106:922-24
24. Zhou W, Inada M, Lee TP, et al. 2005. ADAMTS13 is expressed in hepatic stellate cells. Lab. Invest. 85:780-88
25. NiiyaM, UemuraM, Zheng XW, et al. 2006. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J. Thromb. Haemost. 4:1063-70
26. Watanabe N, Ikeda H, Kume Y, et al. 2009. Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis. Thromb. Haemost. 102:389-96
27. Kume Y, Ikeda H, Inoue M, et al. 2007. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS Lett. 581:1631-34
28. Shang D, Zheng XW, Niiya M, et al. 2006. Apical sorting of ADAMTS13 in vascular endothelial cells andMadin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 108:2207-15
29. Suzuki M, Murata M, Matsubara Y, et al. 2004. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem. Biophys. Res. Commun. 313:212-16
30. Manea M, Kristoffersson A, Schneppenheim R, et al. 2007. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br. J. Haematol. 138:651-62
31. Tauchi R, Imagama S, Ohgomori T, et al. 2012. ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury. Neurosci. Lett. 517:1-6
32. Mannucci PM, Capoferri C, Canciani MT. 2004. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br. J. Haematol. 126:213-18
33. Cao WJ, Niiya M, Zheng XW, et al. 2008. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J. Thromb. Haemost. 6:1233-35
34. Westwood JP, Langley K, Heelas E, et al. 2014. Complement and cytokine response in acute thrombotic thrombocytopenic purpura. Br. J. Haematol. 164:858-66
35. Shen L, LuG, DongN, et al. 2013. Simvastatin increases ADAMTS13 expression in podocytes. Thromb. Res. 132:94-99
36. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. 1996. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-Darginine vasopressin in humans. Blood 88:2951-58
37. Hattori R, Hamilton KK, McEver RP, et al. 1989. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J. Biol. Chem. 264:9053-60
38. Huang J, Motto DG, Bundle DR, et al. 2010. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood 116:3653-59
39. Bao J, Xiao J, Mao Y, et al. 2014. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-Thiol-dependent manner. Arterioscler. Thromb. Vasc. Biol. 34:397-407
40. Mannucci PM. 2000. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 6(Suppl. 1):60-67
41. Choi H, Aboulfatova K, Pownall HJ, et al. 2007. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J. Biol. Chem. 282:35604-11
42. YehHC, Zhou Z, Choi H, et al. 2010. Disulfide bond reduction of vonWillebrand factor by ADAMTS-13. J. Thromb. Haemost. 8:2778-88
43. McGrath RT, van den Biggelaar M, Byrne B, et al. 2013. Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood 122:4107-10
44. Majerus EM, Anderson PJ, Sadler JE. 2005. Binding of ADAMTS13 to von Willebrand factor. J. Biol. Chem. 280:21773-78
45. Jin SY, Skipwith CG, Shang D, et al. 2009. von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size. J. Thromb. Haemost. 7:1749-52
46. Skipwith CG, Cao W, Zheng XL. 2010. Factor VIII and platelets synergistically accelerate cleavage of vonWillebrand factor by ADAMTS13 under fluid shear stress. J. Biol. Chem. 285:28596-603
47. Cao W, Krishnaswamy S, Camire RM, et al. 2008. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc. Natl. Acad. Sci. USA 105:7416-21
48. Furlan M, Robles R, Galbusera M, et al. 1998. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 339:1578-84
49. Zhang X, Halvorsen K, Zhang CZ, et al. 2009. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324:1330-34
50. Lynch CJ, Lane DA, Luken BM. 2014. Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF. Blood 123:2585-92
51. Xu AJ, Springer TA. 2012. Calcium stabilizes the von Willebrand factor A2 domain by promoting refolding. Proc. Natl. Acad. Sci. USA 109:3742-47
52. Tao Z, Wang Y, Choi H, et al. 2005. Cleavage of ultralarge multimers of von Willebrand factor by C-Terminal-Truncated mutants of ADAMTS-13 under flow. Blood 106:141-43
53. Ai J, Smith P, Wang S, et al. 2005. The proximal carboxyl-Terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J. Biol. Chem. 280:29428-34
54. Jin SY, Skipwith CG, Zheng XL. 2010. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood 115:2300-10
55. GaoW, Anderson PJ, Sadler JE. 2008. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 112:1713-19
56. Zhang P, Pan W, Rux AH, et al. 2007. The cooperative activity between the carboxyl-Terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 110:1887-94
57. Tao Z, Peng Y, Nolasco L, et al. 2005. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 106:4139-45
58. Banno F, Chauhan AK, Kokame K, et al. 2009. The distal carboxyl-Terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 113:5323-29
59. Xiao J, Jin SY, Xue J, et al. 2011. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 31:2261-69
60. Zheng XL, Wu HM, Shang D, et al. 2010. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 95:1555-62
61. Zheng XL. 2013. Structure-function and regulation of ADAMTS-13 protease. J. Thromb. Haemost. 11(Suppl. 1):11-23
62. Pos W, Sorvillo N, Fijnheer R, et al. 2011. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica 96:1670-77
63. Jian C, Xiao J, Gong L, et al. 2012. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 119:3836-43
64. Arbus GS. 1997. Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome. Kidney Int. Suppl. 58:S91-96
65. Kavanagh D, Goodship TH, Richards A. 2013. Atypical hemolytic uremic syndrome. Semin. Nephrol. 33:508-30
66. Dragon-Durey MA, Blanc C, Garnier A, et al. 2010. Anti-factor H autoantibody-Associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin. Thromb. Hemost. 36:633-40
67. Kavanagh D, Pappworth IY, Anderson H, et al. 2012. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-Associated or an epiphenomenon?. Clin. J. Am. Soc. Nephrol. 7:417-26
68. Delvaeye M, Noris M, De Vriese A, et al. 2009. Thrombomodulin mutations in atypical hemolyticuremic syndrome. N. Engl. J. Med. 361:345-57
69. Lemaire M, Fremeaux-Bacchi V, Schaefer F, et al. 2013. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45:531-36
70. ZhengXL, KaufmanRM, Goodnough LT, et al. 2004. Effect of plasma exchange on plasmaADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103:4043-49
71. Coppo P, Wolf M, Veyradier A, et al. 2006. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-Acquired thrombotic thrombocytopenic purpura. Br. J. Haematol. 132:66-74
72. Barrows BD, Teruya J. 2014. Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura. Arch. Pathol. Lab. Med. 138:546-49
73. Furlan M, Lammle B. 1998. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin. Haemat. 11:509-14
74. Gerritsen HE, Turecek PL, Schwarz HP, et al. 1999. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb. Haemost. 82:1386-89
75. Knovich MA, Lawson HL, Burke MH, et al. 2008. Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: clinical applications and comparison with immunoblot method. Am. J. Hematol. 83:654-56
76. Kokame K, Nobe Y, Kokubo Y, et al. 2005. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br. J. Haematol. 129:93-100
77. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. 2010. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115:1500-11
78. Meyer SC, Sulzer I, Lammle B, et al. 2007. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J. Thromb. Haemost. 5:866-67
79. Muia J, GaoW, Haberichter SL, et al. 2013. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 11:1511-18
80. Studt JD, Kremer Hovinga JA, Antoine G, et al. 2005. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 105:542-44
81. Mancini I, Valsecchi C, Lotta LA, et al. 2014. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb. Haemost. 112:297-303
82. Mackie I, Langley K, Chitolie A, et al. 2013. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb. Haemost. 109:488-96
83. Bianchi V, Robles R, Alberio L, et al. 2002. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100:710-13
84. Ono T, Mimuro J, Madoiwa S, et al. 2006. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107:528-34
85. Furlan M, Lammle B. 2001. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of vonWillebrand factor-cleaving protease. Best Prac. Res. Clin. Haemat. 14:437-54
86. NiiyaM, EndoM, Shang D, et al. 2009. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol. Ther. 17:34-41
87. Laje P, Shang D, Cao W, et al. 2009. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood 113:2172-80
88. Jin SY, Xiao J, Bao J, et al. 2013. AAV-mediated expression of anADAMTS13variant prevents shigatoxininduced thrombotic thrombocytopenic purpura. Blood 121:3825-29, S1-3
89. Cataland SR, Wu HM. 2014. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 123:2478-84
90. Wu TC, Yang S, Haven S, et al. 2013. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 11:1925-27
91. Caramazza D, Quintini G, Abbene I, et al. 2010. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 50:2753-60
92. Callewaert F, Roodt J, Ulrichts H, et al. 2012. Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 120:3603-10
93. Knobl P, Jilma B, Gilbert JC, et al. 2009. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 49:2181-85
94. Matsukawa M, Kaikita K, Soejima K, et al. 2007. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am. J. Cardiol. 100:758-63
95. Hanson E, Jood K, Nilsson S, et al. 2009. Association between genetic variation at the ADAMTS13 locus and ischemic stroke. J. Thromb. Haemost. 7:2147-48
96. Stepanian A, Cohen-Moatti M, Sanglier T, et al. 2011. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler. Thromb. Vasc. Biol. 31:1703-9
97. Larkin D, de Laat B, Jenkins PV, et al. 2009. Severe Plasmodium falciparum malaria is associated with circulating ultra-large vonWillebrandmultimers and ADAMTS13 inhibition. PLOS Pathog. 5:e1000349
98. Fujioka M, Hayakawa K, Mishima K, et al. 2010. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 115:1650-53
99. Gandhi C, Khan MM, Lentz SR, et al. 2012. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 119:2385-91
100. Jin SY, Tohyama J, Bauer RC, et al. 2012. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler. Thromb. Vasc. Biol. 32:1817-23